Exact Sciences Files Second Module of PMA Application with FDA | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences today said that it has filed the second module of a premarket approval application for its Cologuard colorectal cancer screening test with the US Food and Drug Administration.

The module, which was submitted to the agency on Friday, was comprised of the required studies and documentation establishing the analytical sensitivity and specificity, cross-reactivity, and other similar studies on the test. The firm said that the third and final module will include clinical data from its DeeP-C trial.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.